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Vascular remodeling is a feature of chronic inflamma-
tion during which capillaries transform into venules
that expand the region of the vasculature in which
leakage and leukocyte emigration both occur. Recently,
we found that angiopoietin/Tie2 receptor signaling
drives the transformation of capillaries into venules at
an early stage of the sustained inflammatory response
in the airways of mice infected with Mycoplasma pul-
monis. However, the precise contributions of both an-
giopoietin-1 (Ang1) and angiopoietin-2 (Ang2) are not
clear. In this study, we sought to determine the contri-
bution of Ang2 to this vascular remodeling. Ang2mRNA
expression levels increased and phosphorylated Tie2
immunoreactivity in mucosal blood vessels decreased,
indicative of diminished receptor signaling after infec-
tion. Selective inhibition of Ang2 throughout the infec-
tion by administration of either of two distinct function-
blocking antibodies reduced the suppression of Tie2
phosphorylation and decreased the remodeling of mu-
cosal capillaries into venules, the amount of leukocyte
influx, and disease severity. These findings are consis-
tent with Ang2 acting as an antagonist of Tie2 receptors
and the reduction of Tie2 phosphorylation in endothe-
lial cells rendering the vasculature more responsive
to cytokines that promote both vascular remodeling
and the consequences of inflammation after M. pul-
monis infection. By blocking such changes, Ang2 in-
hibitors may prove beneficial in the treatment of sus-
tained inflammation in which vascular remodeling,
leakage, and leukocyte influx contribute to its patho-
physiology. (Am J Pathol 2010, 177:000–000; DOI:
10.2353/ajpath.2010.100059)
Vascular remodeling is a well-documented feature of
chronic inflammatory airway diseases such as asthma
and chronic bronchitis.1–4 Such persistent inflamma-
tory conditions are accompanied by changes in the
molecular phenotype of endothelial cells and in the
structure and function of blood vessels that contribute
to the pathophysiology.5
Vascular endothelial growth factor (VEGF) and other
growth factors drive angiogenesis in tumors and macular
degeneration. Less is known about cytokines that pro-
mote vascular remodeling in inflammation, where blood
vessels can undergo phenotypic changes in the absence
of sprouting angiogenesis. VEGF is not involved in the
vascular remodeling that occurs soon after infection of
the murine respiratory pathogen Mycoplasma pulmo-
nis,6,7 but tumor necrosis factor- (TNF-) and related
cytokines are likely contributors.8,9
Angiopoietins (Ang1, 2, and 3 in mice and Ang1, 2,
and 4 in human) are key regulators of vascular remodel-
ing, maturation, and stability through effects on Tie2 re-
ceptor signaling in endothelial cells.10 Angiopoietins are
also important regulators of inflammatory responses,11
but their precise roles are complex.
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The conventional view is that Ang1 has anti-inflamma-
tory properties and Ang2 has pro-inflammatory proper-
ties. Ang1 promotes endothelial cell stability by inducing
Tie2 phosphorylation (p-Tie2).12,13 Ang1 protects against
airway inflammation and hyperreactivity in asthma,14,15
reduces thrombin-induced interleukin-8 production and
neutrophil adhesion,16 and decreases VEGF-induced up-
regulation of inflammatory adhesion molecules.17 Ang2,
which is dynamically regulated, can be rapidly re-
leased from endothelial cell Weibel-Palade bodies and
can antagonize the action of Ang1 by binding Tie2
without inducing phosphorylation.18,19 Ang2 sensitizes
endothelial cells to TNF- and can exaggerate inflam-
matory responses.11,20
Under certain conditions, Ang2 can activate Tie2 like
Ang1, instead of opposing the actions of Ang1.21,22 As
an example, overexpression of Ang2 results in micro-
vascular enlargement similar to that found after Ang1
overexpression.23 Both Ang1 and Ang2 can also have
pro-inflammatory effects. Induction of P-selectin trans-
location in endothelial cells, activation of PAF synthesis
in endothelial cells, and promotion of neutrophil acti-
vation, adhesion, and chemotaxis are examples.24–27
The usual explanation of these diverse effects is that
the actions of Ang1 and Ang2 on Tie2 are dose- and
context-dependent.
In a previous report, we describe that Ang1 protein
and Ang2 protein both accumulate in mouse airways
after M. pulmonis infection and that neutralization of an-
giopoietins by soluble Tie2 decoy receptors that seques-
ter Tie2 ligands reduces vascular remodeling in this set-
ting of sustained airway inflammation.28 Because the
soluble receptors neutralized all Tie2 ligands, the ap-
proach did not distinguish the contributions of Ang1 from
those of Ang2 and did not learn whether the angiopoietin
proteins measured were intracellular or were free to act
on endothelial cell Tie2 receptors.
In the present study we used M. pulmonis infection
as a model of sustained inflammation to test the con-
cept that Ang2 promotes vascular remodeling by sup-
pressing Tie2 signaling, which thereby supports the
pro-inflammatory actions of TNF- and other cyto-
kines.7–9 Our approach was to compare, before and
after infection, the amounts of Ang1 and Ang2 mRNA
expression and Tie2 phosphorylation and to determine
the Ang2-dependence of infection-related vascular re-
modeling, adhesion molecule expression, and leuko-
cyte influx by inhibiting Ang2 with a selective function-
blocking antibody.
We found distinctive changes involving Ang1, Ang2,
and p-Tie2 after M. pulmonis infection: Ang1 mRNA ex-
pression decreased, Ang2 mRNA expression increased,
and p-Tie2 immunoreactivity decreased in mucosal blood
vessels. Importantly, selective inhibition of Ang2 during
infection not only blocked the change in p-Tie2, but also
reduced the vascular remodeling, leukocyte influx, and
infection severity. These findings are consistent with
Ang2 having a pro-inflammatory action in this model by
promoting vascular remodeling.
Materials and Methods
Model of Airway Inflammation in Mice
Male pathogen-free C57BL/6 mice (Charles River, Hollis-
ter, CA), housed under barrier conditions, were anesthe-
tized by intramuscular injection of ketamine (10 mg/kg)
and xylazine (20 mg/kg) and then infected by intranasal
inoculation of 50 l of broth containing 106 CFU of strain
CT7 M. pulmonis organisms (derived from UAB CT29),
half of the dose into each nostril.30 Mice were studied 1,
3, 7, or 14 days after inoculation. All experimental proce-
dures were approved by the Institutional Animal Care and
Use Committee of the University of California at San
Francisco.
Ang2 Function-Blocking Antibodies
Function-blocking monoclonal anti-Ang2 antibody
REGN145 (5 mg/kg, Regeneron) or monoclonal antibody
(mAb) 3.19.3 (10 mg/kg, MedImmune)31 or isotype-
matched control IgG antibody was injected intraperitone-
ally into mice every other day for 7 days beginning 1 day
before infection. REGN145 is a human monoclonal anti-
body with an estimated equilibrium dissociation constant
(kDa) for native human Ang2 of about 50 pmol/L and
inhibits Ang2 with approx 500-fold greater potency than it
inhibits Ang1. REGN145 has similar specificity and po-
tency for mouse angiopoietins (Thurston et al, unpub-
lished results). The human monoclonal antibody 3.19.3
has a kDa for human Ang2 of 86 pmol/L and binds Ang2
with 500-fold or greater affinity than for Ang1. The EC50
value of mAb 3.19.3 was 478 pmol/L for human Ang2 and
194 nmol/L for human Ang1 in a cell-based assay.
Values for mouse angiopoietins were in the same range.
Immunohistochemistry
Mice were anesthetized and perfused through the left
ventricle for 2 minutes with 1% paraformaldehyde in
PBS, pH 7.4. Tracheas were removed, immersed in
fixative for an additional 1 hour and stained as whole-
mounts. The following primary antibodies were used for
immunohistochemistry: PECAM-1 (CD31, hamster anti-
mouse PECAM-1, clone 2H8, 1:500, Fisher), P-selectin
(CD62P, rat anti-mouse, BD Biosciences), CD11b (rat
anti-mouse CD11b, clone M1/70; eBioscience), Tie2 (rat
anti-mouse, Tek4, eBioscience), p-Tie2 (Y992, rabbit anti-
mouse, R&D Systems), and Ang2 (LS-B58, LifeSpan
Biosciences). Secondary antibodies were conjugated
to fluorescein isothiocyanate, Cy3, or Cy5 (Jackson
ImmunoResearch, West Grove, PA). Tracheas from
pathogen-free mice were compared to those from mice
infected for 7 or 14 days by staining with of the anti-
bodies, except p-Tie2 and CD11b, where the staining
was impaired by poor penetration into the thickened
tracheal whole mounts.
2 Tabruyn et al
AJP December 2010, Vol. 177, No. 6
balt2/zjh-jpath/zjh-jpath/zjh01210/zjh8899-10a xppws S1 10/5/10 13:23 4/Color Figure(s): F1-F7 Art: AJP10-0059 Input-cs
Imaging
Digital images were acquired with a Zeiss Axiophot
fluorescence microscope equipped with single, dual,
and triple fluorescence filters and a low-light, 3-chip,
charge-coupled device (CCD) camera (CoolCam, Sci-
Measure, Decatur, GA, 640  480 pixel RGB-color).
This camera also enabled real-time viewing and mea-
suring of blood vessels using custom software. Confo-
cal images were obtained with a Zeiss LSM-510 con-
focal microscope with Argon, Helium-Neon, and UV
lasers (512  512 or 1024  1024 pixel RGB-color) and
AIM 3.2.2 software.
Measurement of Vascular Remodeling
The diameter of capillaries in the tracheal mucosa was
measured at the rostro-caudal midpoint of cartilage rings,
which was roughly halfway between the arteriole and
venule.32 Five or more vessels were measured over each
of 10 cartilage rings in each trachea while viewing real-
time fluorescent images of 960  1280 m regions of
tissue (10 objective, 1 Optovar).
Measurement of Immunoreactivity
Amounts of CD11b immunoreactivity of leukocytes and
P-selectin immunoreactivity of blood vessels were
measured in digital fluorescence images of regions of
tracheal mucosa measuring 960  1280 m (10 objec-
tive, 1 Optovar) over cartilage rings in tracheal whole-
mounts. Five regions were assessed in each trachea,
beginning with the second cartilage ring caudal to the
larynx and continuing consecutively toward the bronchi.
Area density of CD11b or P-selectin immunoreactivity
(red pixels) was calculated as the proportion of total
pixels having a fluorescence intensity greater than back-
ground based on a threshold value of 20 in the range 0
255 by using ImageJ software (http://rsb.info.nih.gov/ij).33
The overall mean for each group was calculated from the
average of all values in each mouse.
RNA Extraction and Quantitative Reverse
Transcription-PCR
RNAwas isolated from tracheas using the RNeasy Plus Mini
isolation kit (Qiagen). RNA yield and purity were determined
by spectrophotometry. cDNAs were synthesized with 1 g
of total RNA using the cDNA synthesis kit (Roche Applied
Science). Quantitative reverse transcription (qRT) PCR was
performed with Kapa SYBR Fast qRT-PCR master mix
(Kapa Biosystems, Cambridge, MA) using a BioRad MyIQ
detection system (Bio-Rad). The relative expression of each
target gene was normalized to the expression of -actin by
calculation of the difference between the Ct target and the
Ct reference gene, where Ct is the fractional PCR cycle
number at which the reporter fluorescence is greater than
















Values are expressed as means  SEM with five mice per
group except with indicated otherwise. All of the experi-
ments were repeated twice. The significance of differences
among groups was assessed by analysis of variance (anal-
ysis of variance) followed by the Dunn-Bonferroni posthoc
test for multiple comparisons with differences considered
significant where P  0.05.
Figure 1. Vascular enlargement after M. pulmonis infection. A–C: Con-
focal microscopic images of blood vessels (green, PECAM-1) in tracheal
whole mounts comparing capillaries in pathogen-free mouse (A, arrow)
to enlarged, remodeled vessels (arrows) in mice infected with M. pul-
monis for 7 days (B) or 14 days (C). D: Measurements of vessels at
midpoint of cartilage ring (dotted line) show the magnitude of vascular
enlargement after infection. *P  0.05 compared with pathogen-free.
Scale bars  100 m.
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Results
Vascular Remodeling after M. pulmonis
Infection
In the trachea of pathogen-free mice, capillaries over
cartilaginous rings were organized in a distinctive ladder-
like pattern (Figure 1A). Most arterioles and venules were
located in regions of the mucosa between cartilage rings
(Figure 1A). Conspicuous changes were evident in the
tracheal vasculature after M. pulmonis infection. At 7 and
14 days after infection, capillaries were conspicuously
enlarged but had no evidence of new blood vessel
growth by sprouting angiogenesis (Figure 1, BC). The
diameter of the remodeled vessels was on average 60%
greater than the pathogen-free value at 7 days after
infection and 75% greater at 14 days (Figure 1D).
Expression of Ang1 and Ang2 after M.
pulmonis Infection
Measurements by qRT-PCR of tracheas of pathogen-free
mice revealed roughly equal amounts of Ang1 and Ang2
mRNA when expressed as copy number relative to -ac-
tin (Figure 2, AC). On days 3 and 7 after M. pulmonis
infection, Ang1 mRNA expression was significantly less
than in pathogen-free mice (Figure 2, AB). Ang2 ex-
pression was unchanged on day 3, but on day 7 was
significantly greater than the pathogen-free value. At day
14 of infection, Ang1 expression was back to the base-
line, but Ang2 remained increased (Figure 2B). Because
of the early reduction in Ang1 and subsequent sustained
increase in Ang2, the mRNA the ratio of Ang2 to Ang1
was significantly greater at 3, 7 and 14 days after infec-
tion (Figure 2C).
The distribution of Ang2 immunoreactivity in relation to
PECAM-1 staining of blood vessels was assessed by
immunohistochemical staining of tracheal whole-mounts
before and after M. pulmonis infection. Ang2 immunore-
activity was found in capillaries of pathogen-free tra-
cheas (Figure 2D) and in remodeled vessels at 7 days
after infection, when capillaries had enlarged and ac-
quired the phenotype of venules (Figure 2E). Because
the remodeled vessels had a conical shape (Figure 1,
BC), those sampled near the midline (Figure 2E) were
not as large as those downstream.
Ang2 immunoreactivity did not strictly colocalize
with PECAM-1. Staining with the hamster anti-mouse
PECAM-1 antibody was largely membrane-associated
and strongest at endothelial cell borders. However, most
Ang2 staining was not in the membrane but was instead
cytoplasmic, presumably in Weibel-Palade bodies19 that
could not be individually resolved in tracheal whole
mounts. Therefore, PECAM-1 and Ang2 were associated
with the same blood vessels but had slightly different
distributions within the vessel wall.
Distribution of Tie2 in Airway Vasculature
Tie2 immunoreactivity was present throughout the vascu-
lature of pathogen-free tracheas and largely matched the
distribution of PECAM-1 (Figure 3A). The distribution and
Figure 2. Increase in Ang2 expression after M.
pulmonis infection. A and B: qRT-PCR measure-
ments of expression of Ang1 mRNA (A) and Ang2
mRNA (B) in trachea of pathogen-free mice and
mice infected with M. pulmonis for 1, 3, 7, or 14
days. C: Ratio of qRT-PCR measurements of Ang2
mRNA to Ang1 mRNA. *P  0.05 compared to
pathogen-free (day 0). D and E: Confocal micro-
graphs of vessels in tracheal whole mounts show-
ing Ang2 (red) and PECAM-1 (green) immunore-
activities of a capillary in a pathogen-free mouse
(D) and a remodeled vessel over a cartilage ring in
a mouse infected with M. pulmonis for 7 days (E).
Scale bars  30 m (D and E).
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intensity of Tie2 immunoreactivity was about the same in
remodeled blood vessels after M. pulmonis infection for 7
days (Figure 3B) or 14 days. Similarly, overall expression
of Tie2 mRNA in the trachea was essentially unchanged
after infection for 1 to 14 days (Figure 3C).
p-Tie2 immunoreactivity was clear and uniformly dis-
tributed in the vasculature of pathogen-free tracheas
(Figure 3, D and F) but was faint or absent in the
remodeled vasculature after 7 days of infection (Figure
3, E and G, and Supplemental Figure S1, at http://ajp.
amjpathol.org), consistent with continued presence of
Tie2 receptors in endothelial cells but reduced activa-
tion after infection.
Reduction in Vascular Remodeling by Ang2
Blockade with REGN145
The contribution of Ang2 to vascular remodeling after M.
pulmonis infection was tested by administration of a func-
tion-blocking anti-Ang2 antibody, REGN145, throughout
the infection. Tracheal capillaries in mice treated with
REGN145 three times a week starting the day before
infection were smaller at 7 days after infection than in
mice treated with control IgG (Figure 4, AC). Measure-
ments revealed that the enlargement of blood vessels
over cartilage rings after 7 days of infection was 70% less
in mice treated with REGN145 than in mice treated with
IgG (Figure 4D). Similarly, qRT-PCR measurements of
expression of PECAM-1 and the endothelial cell-specific
adherens junction protein VE-cadherin showed a signifi-
cant increase after 7 days of infection in mice treated with
control IgG, consistent with vascular enlargement, but
not in mice treated with REGN145 (Figure 4, E and F).
Similarly, the reduction in p-Tie2 immunoreactivity found
after infection was less in mice treated with REGN145
(Figure 4, G and H). Together, these results fit with Ang2
blockade by REGN145 during infection leading to greater
Tie2 activation and less vascular remodeling.
Reduction in P-Selectin Expression by Ang2
Blockade with REGN145
P-selectin immunoreactivity was not present in capillaries
(arrows) in the trachea of pathogen-free mice (Figure 5A),
and was faint in venules (arrowheads) of these mice. How-
ever, after M. pulmonis infection for 7 days, P-selectin was
unusually strong in venules, including the remodeled ves-
sels (arrow) over a cartilage ring where capillaries were
normally located (Figure 5B). The change in vessel pheno-
type from capillary to venule fits with published evidence
showing that the remodeled vessels acquire multiple mark-
ers of a venous identity (P-selectin, E-selectin, ICAM-1,
EphB4).28
P-selectin staining was much weaker in the vascu-
lature of infected mice treated with REGN145 (Figure
5C). Measurements revealed that the 20-fold increase
in P-selectin immunofluorescence after infection was
reduced by 70% when the infection was accompanied
by REGN145 (Figure 5D). Similarly, tracheal expres-
sion of P-selectin mRNA was 10-fold greater after in-
fection for 7 days and was reduced by 70% in infected
mice treated with REGN145 (Figure 5E). Changes in
expression of E-selectin (Figure 5F) were similar in
magnitude.
Reduction in Vascular Remodeling by Ang2
Blockade with mAb 3.19.3
A second function-blocking anti-Ang2 antibody (mAb
3.19.3) gave results consistent with the effects of
REGN145 and provided further support for the contribu-
tion of Ang2 to vascular remodeling after M. pulmonis
infection. Vascular remodeling, reflected by increase in
Figure 3. Decrease in Tie2 expression after M. pulmonis infection. A and
B: Confocal micrographs showing the similarity of Tie2 (red) in tracheal
capillary of pathogen-free mouse (A) and remodeled vessel in mouse
infected for 7 days (B). PECAM-1, green. C: qRT-PCR measurements
showing no difference in Tie-2 mRNA, expressed relative to -actin, in
trachea of pathogen-free mice (day 0) and mice infected for 1, 3, 7, or 14
days. D–G: Confocal micrographs at lower (D and E) and higher (F and
G) magnifications showing weaker p-Tie2 immunoreactivity (red) in re-
modeled vessels after infection for 7 days (E and G) than in tracheal
capillary of pathogen-free mouse (D and F). Images were acquired with
the same fluorescence intensity setting. Scale bars: 30 m (A and B); 100
m (D and E); 30 m (F and G).
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vessel diameter and in P-selectin immunoreactivity after
infection, was greater in mice treated with the control IgG
than in corresponding mice treated with the Ang2 inhib-
itor mAb 3.19.3 (Figure 6, AC). Measurements showed
that the amount of vessel enlargement was 50% less
when the infection was accompanied by mAb 3.19.3
(Figure 6D). Similarly, qRT-PCR measurements of ex-
pression of PECAM-1, VE-cadherin, P-selectin, and E-
Figure 4. Reduction in vascular enlargement and p-Tie2 suppression by Ang2 blockade with REGN145. AC: Confocal micrographs comparing the size of blood vessels
(green, PECAM-1) in tracheal whole mounts from a pathogen-free mouse (A) and mice infected with M. pulmonis for 7 days with concurrent treatment with normal IgG
(B) or REGN145 5 mg/kg (C). Arrows mark blood vessel measurement site over midpoint of cartilage ring. D: Contrasting mean vessel diameters in tracheas of
pathogen-free mice and infected mice treated with IgG or REGN145 for 7 days. E and F: qRT-PCR measurements of PECAM-1 (E) and VE-cadherin (F) in tracheas of
pathogen-free mice and infected mice treated with IgG or REGN145 for 7 days. *P 0.05 compared to pathogen-free; #P 0.05 compared to infected mice treated with
IgG. G and H: Pairs of confocal micrographs showing PECAM-1 (green) and p-Tie2 (red) immunoreactivities of tracheal blood vessels after infection for 7 days. p-Tie2
is faint or absent on vessels in infected mouse that received IgG (G) but is stronger on vessels in infected mouse treated with REGN145 (H). Scale bars: 150 m (AC)
or 100 m (G and H).
6 Tabruyn et al
AJP December 2010, Vol. 177, No. 6
balt2/zjh-jpath/zjh-jpath/zjh01210/zjh8899-10a xppws S1 10/5/10 13:23 4/Color Figure(s): F1-F7 Art: AJP10-0059 Input-cs
F6
selectin were about 75% lower in infected mice treated
with mAb 3.19.3 than with IgG (Figure 6, E and F).
Reduction in Leukocyte Influx and Infection
Severity by Ang2 Blockade
The number of CD11b-positive cells in the tracheal mu-
cosa was used to determine whether increased expres-
sion of P-selectin and E-selectin on remodeled blood
vessels after M. pulmonis infection was accompanied by
greater leukocyte influx. In pathogen-free tracheas,
CD11b immunoreactive cells were sparse, and most
around venules in intercartilaginous regions (Figure 7A).
By comparison, at 7 days after infection, CD11b-positive
cells were abundant throughout the trachea (Figure 7B,
control IgG), but when Ang2 was inhibited by REGN145
during the infection, fewer leukocytes were located in the
mucosa over cartilage rings (Figure 7C). CD11b immu-
noreactivity in these regions was 70% less in infected
mice treated with REGN145 than in those treated with IgG
(Figure 7D). CD11b RNA expression measured by qRT-
PCR was significantly lower in infected mice treated with
REGN145 than in mice treated with the control IgG (Fig-
ure 7E). Expression of TNF- was also significantly lower
in REGN145-treated mice (Figure 7F).
Infection severity was also assessed by qRT-PCR
measurements of expression of M. pulmonis 16S rRNA in
the trachea (Figure 7G). The amount of M. pulmonis 16S
rRNA was strongly correlated with P-selectin expression
as an index of vascular remodeling (R2  0.894, P 
0.01). Amount of M. pulmonis 16S rRNA was significantly
less in infected mice treated with REGN145 or with mAb
3.19.3 than with IgG, consistent with reduced overall
severity of infection (Figure 7H).
Discussion
The present study sought to determine whether Ang2
drives vascular remodeling in the respiratory tract after
M. pulmonis infection. The remodeling results from endo-
thelial cell proliferation—not vasodilatation or sprouting
angiogenesis—and leads to circumferential enlargement
of capillaries.30,34 In the process, capillaries acquire a
venular phenotype, reflected by increased immunoreac-
tivity for multiple molecules typical of venules, including
P-selectin, E-selectin, ICAM-1, and EphB4, that supports
leukocyte adherence and migration and other venule-
specific features of the inflammatory response.28,34,35
Gene expression arrays have documented the in-
crease in expression of leukocyte adhesion molecules
at 1 and 12 weeks after infection (at 1 week: P-selectin,
10-fold; E-selectin, 43-fold; and ICAM-1 fourfold com-
pared to pathogen-free; McDonald and Thurston, un-
published data).
Previous reports have shown the importance of Tie2
signaling in blood vessel remodeling and stabiliza-
tion13,36 and have implicated angiopoietins as factors
Figure 5. Reduction in adhesion molecule ex-
pression by Ang2 blockade with REGN145.
AC: Confocal micrographs of P-selectin immu-
noreactivity (red) in blood vessels (green,
PECAM-1) of tracheal whole mounts. P-selectin
immunoreactivity in pathogen-free trachea (A) is
absent in capillaries (arrows) and faint in
venules (arrowhead). After M. pulmonis infec-
tion, P-selectin is strong in remodeled vessels
(arrow) of mouse treated with IgG (B) but weak
in vessels (arrow) of mouse treated with
REGN145 at a dose of 5 mg/kg (C). D: Fractional
area of P-selectin immunoreactivity in regions of
vessels over cartilage in pathogen-free mice and
in infected mice treated concurrently with IgG or
REGN145. E and F: qRT-PCR measurements
comparing expression of P-selectin (E), and E-
selectin (F) mRNA in tracheas of pathogen-free
and infected mice treated with IgG or REGN145
for 7 days. *P 0.05 compared to pathogen-free;
#P  0.05 compared to infected mice treated
with IgG. Scale bars  150 m.
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that drive remodeling of blood vessels and lymphatics
during development37,38 and after M. pulmonis infec-
tion.5,28,39 Angiopoietins are also thought to play a role in
other models of injury and inflammation.14,20,40 However,
uncertainties regarding the relative contributions of Ang1
and Ang2 to vascular remodeling in inflammation war-
ranted further studies and led to our use of multiple
readouts to assess changes in angiopoietins and Tie2
signaling in mouse airways after M. pulmonis infection.
Our experiments revealed that the vascular remodel-
ing present after M. pulmonis infection for 7 days was
accompanied by increased Ang2 mRNA expression,
when Ang2 immunoreactivity was largely restricted to
endothelial cells. Immunoreactivity for p-Tie2 decreased
in remodeled vessels, but overall Tie2 mRNA expression
did not change. Selective inhibition of Ang2 significantly
reduced the decrease in p-Tie2 immunoreactivity and the
vascular remodeling during the infection.
Although the amount of Ang2 immunoreactivity per
endothelial cell was not noticeably increased, M. pulmo-
nis infection is followed by rapid proliferation of endothe-
lial cells, which results in an increase in the population of
endothelial cells and in enlargement of remodeled cap-
illaries and venules.30 The estimated twofold increase in
number of endothelial cells after infection is in scale with
the increase in Ang2 mRNA and is consistent with the
similar increase in VE-cadherin shown in Figure 4F.
The early increase in Ang2 expression and reduction in
p-Tie2 immunoreactivity after M. pulmonis infection are
consistent with the contribution of Ang2 to the suppres-
sion of Tie2 phosphorylation during the remodeling pro-
cess. In support of this, we found that inhibition of Ang2
by two different Ang2 function-blocking antibodies re-
duced vascular remodeling after infection and accompa-
nying changes in expression of PECAM-1, VE-cadherin,
P-selectin, and E-selectin, and in leukocyte influx.
The angiopoietins have been implicated in the regula-
tion vascular permeability in inflammation.5,41,42 Mucosal
edema is a feature of chronic inflammatory airway dis-
eases in general and in M. pulmonis infection in particu-
lar.30,43 The rate of leakage after M. pulmonis infection is
small compared to that after bradykinin, histamine, or
substance P, and therefore difficult to measure.30 How-
ever, the impact of leakage after infection is potentially
much greater because it is continuous and does not
resolve spontaneously, whereas the half-life of leakage
after bradykinin, histamine, or substance P is only a few
minutes.42 The reversibility of the leakage in sustained
inflammation by manipulation of angiopoietin/Tie2 signal-
ing is a promising direction for future research.
Both function-blocking antibodies bind Ang2 with high
affinity (Thurston et al, unpublished data and Brown et al,
201031), but attributing this effect exclusively to Ang2
blockade is dependent on the selectivity of the antibod-
ies. Because the assays used to test antibody specificity
have limitations, a minor contribution of inhibitory activity
on Ang1 or other angiopoietin cannot be excluded. The
two blocking antibodies reduced expression of adhesion
Figure 6. Reduction in vascular remodeling by
Ang2 blockade with mAb 3.19.3. AC: Confocal
micrographs of P-selectin immunoreactivity (red)
in blood vessels (green, PECAM-1) of tracheal
whole mount of pathogen-free mouse and mice
infected with M. pulmonis for 7 days with concur-
rent treatment with 10 mg/kg of isotype control
IgG (B) or mAb 3.19.3 (C). Arrows mark regions
where vessel measurements were made. D: Diam-
eter of tracheal blood vessels measured over mid-
point of cartilage rings in pathogen-free mice and
mice treated with IgG or mAb 3.19.3 during 7-day
infection. E and F: qRT-PCR measurements of ex-
pression of PECAM-1 and VE-cadherin (E) or P-
selectin and E-selectin (F) in tracheas of infected
mice treated with IgG or mAb 3.19.3 for 7 days.
Values after Ang2 blockade by mAb 3.19.3 were
significantly less. *P 0.05 compared to pathogen-
free; #P  0.05 compared to infected mice treated
with IgG. Scale bars  100 m.
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Figure 7. Reduction in leukocyte influx by Ang2 blockade during infection. AC: Confocal micrographs of leukocytes (red, CD11b) and blood vessels (green,
PECAM-1) in regions over cartilage in tracheal whole mount of pathogen-free mouse and mice with M. pulmonis infection for 7 days and concurrent treatment
with 5 mg/kg of isotype control IgG (B) or REGN145 (C). D: Fractional area of CD11b immunoreactivity in mucosa over cartilages of pathogen-free mice and
infected mice treated with IgG or REGN145. E and F: qRT-PCR measurements of expression of CD11b (E), TNF- (F) in tracheas of pathogen-free mice and
infected mice treated with IgG or REGN145 for 7 days, showing significantly lower values after REGN145 (N  15). G: Linear regression (r2  0.89) of P-selectin
expression and M. pulmonis 16S rRNA expression measured by qRT-PCR in tracheas of mice infected for 7 days. H: qRT-PCR measurements of M. pulmonis 16S
rRNA expression in tracheas of pathogen-free mice and mice infected and treated for 7 days with control IgG, REGN145, or mAb 3.19.3. *P  0.05 compared to
pathogen-free; #P  0.05 compared to infected mice treated with IgG. Scale bars  150 m.
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molecules and infection severity to a similar extent.
REGN145 led to somewhat greater reduction in capillary
diameter than mAb 3.19.3, perhaps because of differ-
ences in affinity, pharmacokinetics, or selectivity. None-
theless, the striking similarity of the effects of the two
antibodies during M. pulmonis infection argue that Ang2
promotes vascular remodeling in this model.
Our finding of uniform p-Tie2 immunoreactivity on
blood vessels of normal tracheas supports the concept
that Tie2 is phosphorylated in normal, stable endothelial
cells of adult blood vessels.44 The results linking in-
creased Ang2 expression to reduced Tie2 phosphoryla-
tion after M. pulmonis infection, and conversely, linking
Ang2 blockade to less reduction of p-Tie2, suggest that
Ang2 acts as a Tie2 antagonist and that loss of Tie2
phosphorylation renders the vasculature more respon-
sive to inflammatory cytokines in infected airways. This
mechanism would explain how the actions of TNF- and
Ang2 cooperate in promoting the remodeling of capillar-
ies into venules after M. pulmonis infection.8
How can the decrease in Ang1 mRNA found at 7 days
after infection be reconciled with the increase in Ang1
protein in a previous study?28 Several lines of evidence
help to explain the difference.M. pulmonis infection leads
to a massive influx of leukocytes into the airways and
lungs.30 Most of the Ang1 protein detected as immuno-
reactivity at 7 days is associated with neutrophils,
whereas Ang2 immunoreactivity is in endothelial cells.28
Similarly, purified circulating human neutrophils contain
Ang1—but not Ang2.45
The earlier study found an increase in Ang1 protein
assessed in Western blots,28 and the present study found
a decrease in Ang1 mRNA expression measured by qRT-
PCR. Ang1 is likely to be stored in neutrophils as previ-
ously synthesized protein and not accompanied by a
corresponding level of expression of Ang1 mRNA. Ang1
and VEGF in circulating human neutrophils are released
in equal amounts by phorbol myristate acetate stimula-
tion, but expression of Ang1 mRNA is 92% lower than
expression of VEGF mRNA.45 Neutrophil -granule-asso-
ciated proteins elastase and myeloperoxidase are syn-
thesized during differentiation and stored until secretion
at sites of inflammation.46,47 Ang1 mRNA expression may
be similarly down-regulated during the final steps of neu-
trophil maturation. The release of Ang1 protein from neu-
trophils differs from secretion of VEGF and other proteins
in -granules, because Ang1 is cytosolic instead of in
granules and its release is neither calcium dependent nor
evoked by TNF- or other neutrophil-activating cyto-
kines.45 Vascular remodeling after infection was associ-
ated with increased Ang2 expression and decreased
Tie2 phosphorylation, which are consistent with Ang2-
mediated inactivation of Tie2 signaling as a trigger for the
vascular remodeling. If, when, where, and how much
Ang1 is released and the contribution of neutrophil Ang1
to the response remain to be determined.
TNF- may promote the increase in Ang2 expression
afterM. pulmonis infection. TNF- is known to up-regulate
Ang2 expression in endothelial cells48,49 and to increase
rapidly in expression after M. pulmonis infection.8 TNF-
can also induce expression of adhesion molecules in-
volved in leukocyte influx via Ang2 activation.11,50
Levels of Ang2 in blood or other body fluids increase in
multiple diseases. Higher levels of Ang2 in airway fluid or
blood are associated with more severe disease in pa-
tients with acute lung injury and in infants that develop
bronchopulmonary dysplasia.40,51 Higher levels of Ang2
in sputum correlate with more airway vascular leakiness
in asthma.52,53 High blood levels of Ang2 correlate with
disease severity or poor outcome in patients with sep-
sis,54,55 systemic lupus erythematosus,56 inflammatory
bowel disease,57 and malaria.58
Ang2 blockade reduced the load of M. pulmonis organ-
isms. The anti-inflammatory action of dexamethasone simi-
larly reduces the load of M. pulmonis in the airways.59 Both
of these actions reflect the link between conditions that
influence the growth of the organisms and the magnitude of
the inflammatory response. They also fit with the reciprocal
interdependence of the severity ofM. pulmonis infection and
magnitude of the inflammatory response.60,61 Pro-inflam-
matory factors exacerbate the infection, and anti-inflamma-
tory factors reduce it.
In conclusion, our results show that inhibition of Ang2
stabilizes Tie2 phosphorylation in endothelial cells, reduces
vascular remodeling and expansion of venules that support
leukocyte influx, and reduces the overall severity of M.
pulmonis infection. These findings warrant further studies to
develop a better understanding of the favorable actions of
Ang2 inhibitors in airway inflammation.
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